Do you alter definitive treatment recommendations for oropharynx p16+ cancers based on the new staging?

As you know, the new 8th Edition of the AJCC staging manual redefined prognostic staging for p16/HPV-positive tumors. It is important to note that p16/HPV is therefore not a PROGNOSTIC marker but rather a DIAGNOSTIC biomarker of a different disease entity entirely. The 8th Edition system is based of...

We have not altered definitive treatment recommendations for p16+ oropharyngeal cancer since the introduction of the new AJCC staging.